Apellis Pharmaceuticals, Inc. (APLS)
41.03
0.00 (0.00%)
USD |
NASDAQ |
May 21, 16:00
Apellis Pharmaceuticals Research and Development Expense (TTM) : 286.39M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biogen, Inc. | 1.607B |
| Eli Lilly & Co. | 14.11B |
| Agios Pharmaceuticals, Inc. | 342.68M |
| Spyre Therapeutics, Inc. | 190.44M |
| Scholar Rock Holding Corp. | 209.98M |